Bischof P, Tseng L, Brioschi P A, Herrmann W L
Hum Reprod. 1986 Nov;1(7):423-6. doi: 10.1093/oxfordjournals.humrep.a136445.
Cancer antigen 125 (CA125) is an antigenic determinant defined by a murine monoclonal antibody and is present on the surface of some ovarian tumours. Using an immunoradiometric assay CA125 immunoreactivity was found in amniotic fluid and decidual extracts, hence the possibility of an endometrial origin of CA125 in pregnant and non-pregnant women was investigated. First-trimester decidual explants produced CA125 in vitro and cycloheximide significantly reduced the concentration of CA125 both in the medium and in the tissue. CA125 was also produced in primary culture of human endometrial stromal cells, its concentration in the medium being significantly higher with cells obtained during the proliferative and early secretory phases compared to those obtained during the late secretory phases. Medroxyprogesterone acetate (MPA, 1 mumol/l) induced a significant inhibition of CA125 production. This effect could be blocked by oestradiol (E2, 36 nmol/l) or the antiprogesterone RU486 (10 mumol/l). In women with endometriosis, the circulating levels of CA125 increased with the severity of the disease and were found to be significantly higher when compared to those of healthy volunteers. Gonadotrophin-releasing hormone or Danatrol therapy significantly reduced the CA125 levels. The endometrium, decidualized or not, seem to be capable of producing CA125, and this production is evidently correlated with endometrial cell growth and/or activity.
癌抗原125（CA125）是一种由鼠单克隆抗体定义的抗原决定簇，存在于某些卵巢肿瘤表面。通过免疫放射分析，在羊水和蜕膜提取物中发现了CA125免疫反应性，因此对孕妇和非孕妇中CA125的子宫内膜起源可能性进行了研究。孕早期蜕膜外植体在体外产生CA125，环己酰亚胺显著降低了培养基和组织中CA125的浓度。人子宫内膜基质细胞原代培养中也产生CA125，与分泌晚期获得的细胞相比，增殖期和分泌早期获得的细胞在培养基中的浓度显著更高。醋酸甲羟孕酮（MPA，1μmol/L）显著抑制CA125的产生。这种作用可被雌二醇（E2，36nmol/L）或抗孕激素RU486（10μmol/L）阻断。在子宫内膜异位症患者中，CA125的循环水平随疾病严重程度增加，并且与健康志愿者相比显著更高。促性腺激素释放激素或丹曲林治疗显著降低了CA125水平。无论是否蜕膜化，子宫内膜似乎都能够产生CA125，并且这种产生显然与子宫内膜细胞生长和/或活性相关。
